An ongoing dialogue on HIV/AIDS, infectious diseases,
March 28th, 2010
Kidneys: Fortunately, We Have Two
Here’s a case over in our Journal Watch: AIDS Clinical Care site: a man with suspected PCP develops rapidly progressive renal failure after being starting on both empiric PCP treatment with TMP-SMX and ART with TDF/FTC plus darunavir/ritonavir.
The specific questions at the end of the case were:
- What do you think is causing the renal failure?
- Would you continue empiric treatment for PCP or try to confirm the diagnosis?
- If you would continue empiric treatment, would you modify it?
- What would you do with his ART? Specifically, would you continue the tenofovir?
- What would be your preferred alternative regimen?
I ran into the nephrologist Jonathan Winston this weekend, who will providing his take on the case shortly. He asked me what actually happened.
Stay tuned …
[Edit: Outcome of case now posted here.]
Categories: Antiretroviral Rounds, Health Care, HIV, Patient Care
Tags: ART, PCP, renal failure, tenofovir
You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.
Comments are closed.
Paul E. Sax, MD
Contributing Editor
NEJM Journal Watch
Infectious Diseases
Biography | Disclosures | Summaries
Learn more about HIV and ID Observations.
Follow HIV and ID Observations Posts via Email
- Dr. Thomas O’Brien — Expert in Antimicrobial Resistance and Giant in His Field (Literally)
- Who’s Going to Get Lenacapavir for HIV Prevention?
- Some ID Things to Be Grateful for This Holiday Season — 2024 Edition
- Marking a Social Media Mass Migration — Until the Next One
- The Riveting Conclusion of How PCP Became PJP
- ID Cartoon Caption Contest (125)
- ID Cartoon Caption Contest #2 Winner — and a New Contest for the Holidays (92)
- Dear Nation — A Series of Apologies on COVID-19 (80)
- How to Induce Rage in a Doctor (77)
- IDSA’s COVID-19 Treatment Guidelines Highlight Difficulty of “Don’t Just Do Something, Stand There” (74)
-
NEJM Journal Watch — Recent Infectious Disease Articles
- When it Comes to Antimicrobial Stewardship, Is a Boost Better Than a Nudge?
- HIV Prevention and Treatment: Updated Recommendations from the International AIDS Society–USA
- Observations from ID and Beyond: Dr. Thomas O'Brien — Expert in Antimicrobial Resistance and Giant in His Field (Literally)
- How Serious Is Artemisinin Partial Resistance in African Malaria Parasites?
- Observations from ID and Beyond: Who's Going to Get Lenacapavir for HIV Prevention?
-
Tag Cloud
- Abacavir AIDS antibiotics antiretroviral therapy ART atazanavir baseball Brush with Greatness CDC C diff COVID-19 CROI darunavir dolutegravir elvitegravir etravirine FDA HCV hepatitis C HIV HIV cure HIV testing ID fellowship ID Learning Unit Infectious Diseases influenza Link-o-Rama lyme disease MRSA PEP Policy PrEP prevention primary care raltegravir Really Rapid Review resistance Retrovirus Conference rilpivirine sofosbuvir TDF/FTC tenofovir Thanksgiving vaccines zoster